[go: up one dir, main page]

MA41544A - Dosages de panobinostat pour le traitement du myélome multiple - Google Patents

Dosages de panobinostat pour le traitement du myélome multiple

Info

Publication number
MA41544A
MA41544A MA041544A MA41544A MA41544A MA 41544 A MA41544 A MA 41544A MA 041544 A MA041544 A MA 041544A MA 41544 A MA41544 A MA 41544A MA 41544 A MA41544 A MA 41544A
Authority
MA
Morocco
Prior art keywords
panobinostat
dosage
treatment
multiple myeloma
myeloma
Prior art date
Application number
MA041544A
Other languages
English (en)
Inventor
Florence Binlich
Renaud Capdeville
Laura Grazioli
Rong Lin
Song Mu
Sofia Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55405393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA41544A publication Critical patent/MA41544A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91188Transferases (2.) transferring nitrogenous groups (2.6)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA041544A 2015-02-19 2016-02-16 Dosages de panobinostat pour le traitement du myélome multiple MA41544A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562118254P 2015-02-19 2015-02-19
US201562119571P 2015-02-23 2015-02-23

Publications (1)

Publication Number Publication Date
MA41544A true MA41544A (fr) 2017-12-26

Family

ID=55405393

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041544A MA41544A (fr) 2015-02-19 2016-02-16 Dosages de panobinostat pour le traitement du myélome multiple

Country Status (19)

Country Link
US (3) US20190388393A1 (fr)
EP (1) EP3258933A1 (fr)
JP (2) JP2018507216A (fr)
KR (1) KR20170118798A (fr)
CN (1) CN107249596A (fr)
AU (2) AU2016221327A1 (fr)
BR (1) BR112017017594A2 (fr)
CA (1) CA2976755A1 (fr)
CL (1) CL2017002116A1 (fr)
IL (1) IL253895A0 (fr)
MA (1) MA41544A (fr)
MX (1) MX2017010577A (fr)
PH (1) PH12017501494A1 (fr)
RU (1) RU2729425C2 (fr)
SG (1) SG11201706521XA (fr)
TN (1) TN2017000356A1 (fr)
TW (1) TW201630602A (fr)
WO (1) WO2016132303A1 (fr)
ZA (1) ZA201705363B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314222B (zh) * 2019-08-07 2023-05-26 上海交通大学医学院附属瑞金医院 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006278718B2 (en) * 2005-08-03 2010-10-07 Secura Bio Inc. Use of HDAC inhibitors for the treatment of myeloma
RS54640B1 (sr) 2006-06-12 2016-08-31 Novartis Ag Soli n-hidroksi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
WO2008100985A2 (fr) * 2007-02-15 2008-08-21 Novartis Ag Combinaisons d'agents thérapeutiques pour le traitement du cancer
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8263578B2 (en) * 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
JP2016512549A (ja) * 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びcyp3a4阻害剤の組み合わせ

Also Published As

Publication number Publication date
RU2729425C2 (ru) 2020-08-06
RU2017132445A3 (fr) 2019-09-23
MX2017010577A (es) 2017-12-07
ZA201705363B (en) 2019-07-31
AU2019200876A1 (en) 2019-02-28
KR20170118798A (ko) 2017-10-25
US20230181529A1 (en) 2023-06-15
US20190388393A1 (en) 2019-12-26
CA2976755A1 (fr) 2016-08-25
BR112017017594A2 (pt) 2018-05-08
JP2018507216A (ja) 2018-03-15
EP3258933A1 (fr) 2017-12-27
US20200093795A1 (en) 2020-03-26
AU2019200876B2 (en) 2020-05-28
AU2016221327A1 (en) 2017-08-31
CL2017002116A1 (es) 2018-05-18
WO2016132303A1 (fr) 2016-08-25
RU2017132445A (ru) 2019-03-20
JP2021105048A (ja) 2021-07-26
PH12017501494A1 (en) 2018-01-29
SG11201706521XA (en) 2017-09-28
IL253895A0 (en) 2017-10-31
TN2017000356A1 (en) 2019-01-16
TW201630602A (zh) 2016-09-01
CN107249596A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3380200A4 (fr) Compositions pour le traitement des cheveux
MA45429A (fr) Polythérapie pour le traitement du cancer
EP3386655C0 (fr) Procédé pour le traitement de déchets
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3383407A4 (fr) Conjugués de cytarabine pour le traitement du cancer
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade